FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

From 40 to 74, the US Preventive Services Task Force advises every two years for screening mammography.

2.

FDA approves rivanetin as the first-line treatment for lung cancer.

3.

Compared to previous estimates, a greater number of patients participate in cancer treatment trials.

4.

'Converging' Evidence of Link Between Air Pollution and Breast Cancer

5.

Doxorubicin-Trabectedin Strategy Boosts Survival in Challenging Sarcoma


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot